Eli Lilly & Co. said it will seek regulatory approval of a migraine drug this year after seeing positive results from late-stage studies, raising hopes for a new class of treatments for the debilitating headaches.
from WSJ.com: US Business http://ift.tt/2r2ytUa
via IFTTT
No comments:
Post a Comment